3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Hodgkin Disease
45
Lymphoma
22
Hematologic Diseases
17
Lymphoma, Large-Cell, Anaplastic
15
Lymphoma, Non-Hodgkin
11
Recurrence
9
Lymphoma, T-Cell
8
Lymphoma, T-Cell, Cutaneous
6
Lymphoma, T-Cell, Peripheral
5
Mycosis Fungoides
3
Lymphoma, Primary Cutaneous Anaplastic Large Cell
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, B-Cell
3
Leukemia, Myeloid, Acute
3
Sezary Syndrome
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Myelodysplastic Syndromes
2
Lymphomatoid Papulosis
2
Enteropathy-Associated T-Cell Lymphoma
2
Dendritic Cell Sarcoma, Interdigitating
2
Testicular Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma, Kaposi
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Melanoma
1
Interventions
pembrolizumab
124
Cisplatin
27
lenvatinib
24
Carboplatin
24
Paclitaxel
19
Docetaxel
16
Fluorouracil
13
Capecitabine
11
Pemetrexed
10
Gemcitabine
10
Saline Solution
8
Oxaliplatin
8
epacadostat
6
Leucovorin
5
Irinotecan
5
Cetuximab
5
olaparib
4
Bevacizumab
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
trifluridine tipiracil drug combination
3
regorafenib
3
enzalutamide
3
durvalumab
3
Nivolumab
3
Etoposide
3
trametinib
2
etoposide phosphate
2
dabrafenib
2
Tretinoin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Brentuximab Vedotin
×
Clear all
NCT02684292
2026-02-18
MK-3475-204
Merck Sharp & Dohme LLC
Phase 3
Completed
304 enrolled
1 FDA